List of Tables
Table 1. Global Cyclic Peptide Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Cyclic Peptide Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Cyclic Peptide Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Cyclic Peptide Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Cyclic Peptide Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Cyclic Peptide Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Cyclic Peptide Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Cyclic Peptide Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cyclic Peptide Service as of 2024)
Table 11. Global Cyclic Peptide Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Cyclic Peptide Service Companies Headquarters
Table 13. Global Cyclic Peptide Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Cyclic Peptide Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Cyclic Peptide Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Cyclic Peptide Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Cyclic Peptide Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Cyclic Peptide Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Cyclic Peptide Service Growth Accelerators and Market Barriers
Table 25. North America Cyclic Peptide Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Cyclic Peptide Service Growth Accelerators and Market Barriers
Table 27. Europe Cyclic Peptide Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Cyclic Peptide Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Cyclic Peptide Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Cyclic Peptide Service Investment Opportunities and Key Challenges
Table 31. Central and South America Cyclic Peptide Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Cyclic Peptide Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Cyclic Peptide Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. GenScript Biotech Corporation Information
Table 35. GenScript Biotech Description and Major Businesses
Table 36. GenScript Biotech Product Features and Attributes
Table 37. GenScript Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. GenScript Biotech Revenue Proportion by Product in 2024
Table 39. GenScript Biotech Revenue Proportion by Application in 2024
Table 40. GenScript Biotech Revenue Proportion by Geographic Area in 2024
Table 41. GenScript Biotech Cyclic Peptide Service SWOT Analysis
Table 42. GenScript Biotech Recent Developments
Table 43. Eurogentec Corporation Information
Table 44. Eurogentec Description and Major Businesses
Table 45. Eurogentec Product Features and Attributes
Table 46. Eurogentec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Eurogentec Revenue Proportion by Product in 2024
Table 48. Eurogentec Revenue Proportion by Application in 2024
Table 49. Eurogentec Revenue Proportion by Geographic Area in 2024
Table 50. Eurogentec Cyclic Peptide Service SWOT Analysis
Table 51. Eurogentec Recent Developments
Table 52. LifeTein Corporation Information
Table 53. LifeTein Description and Major Businesses
Table 54. LifeTein Product Features and Attributes
Table 55. LifeTein Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. LifeTein Revenue Proportion by Product in 2024
Table 57. LifeTein Revenue Proportion by Application in 2024
Table 58. LifeTein Revenue Proportion by Geographic Area in 2024
Table 59. LifeTein Cyclic Peptide Service SWOT Analysis
Table 60. LifeTein Recent Developments
Table 61. Biopharma PEG Scientific Corporation Information
Table 62. Biopharma PEG Scientific Description and Major Businesses
Table 63. Biopharma PEG Scientific Product Features and Attributes
Table 64. Biopharma PEG Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Biopharma PEG Scientific Revenue Proportion by Product in 2024
Table 66. Biopharma PEG Scientific Revenue Proportion by Application in 2024
Table 67. Biopharma PEG Scientific Revenue Proportion by Geographic Area in 2024
Table 68. Biopharma PEG Scientific Cyclic Peptide Service SWOT Analysis
Table 69. Biopharma PEG Scientific Recent Developments
Table 70. AnaSpec Corporation Information
Table 71. AnaSpec Description and Major Businesses
Table 72. AnaSpec Product Features and Attributes
Table 73. AnaSpec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. AnaSpec Revenue Proportion by Product in 2024
Table 75. AnaSpec Revenue Proportion by Application in 2024
Table 76. AnaSpec Revenue Proportion by Geographic Area in 2024
Table 77. AnaSpec Cyclic Peptide Service SWOT Analysis
Table 78. AnaSpec Recent Developments
Table 79. Scitide Corporation Information
Table 80. Scitide Description and Major Businesses
Table 81. Scitide Product Features and Attributes
Table 82. Scitide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Scitide Recent Developments
Table 84. JPT Corporation Information
Table 85. JPT Description and Major Businesses
Table 86. JPT Product Features and Attributes
Table 87. JPT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. JPT Recent Developments
Table 89. CD ComputaBio Corporation Information
Table 90. CD ComputaBio Description and Major Businesses
Table 91. CD ComputaBio Product Features and Attributes
Table 92. CD ComputaBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. CD ComputaBio Recent Developments
Table 94. Creative Peptides Corporation Information
Table 95. Creative Peptides Description and Major Businesses
Table 96. Creative Peptides Product Features and Attributes
Table 97. Creative Peptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Creative Peptides Recent Developments
Table 99. Macrocyclos Corporation Information
Table 100. Macrocyclos Description and Major Businesses
Table 101. Macrocyclos Product Features and Attributes
Table 102. Macrocyclos Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Macrocyclos Recent Developments
Table 104. Peptide Insitute Corporation Information
Table 105. Peptide Insitute Description and Major Businesses
Table 106. Peptide Insitute Product Features and Attributes
Table 107. Peptide Insitute Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Peptide Insitute Recent Developments
Table 109. Genepep Corporation Information
Table 110. Genepep Description and Major Businesses
Table 111. Genepep Product Features and Attributes
Table 112. Genepep Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Genepep Recent Developments
Table 114. Innovagen Corporation Information
Table 115. Innovagen Description and Major Businesses
Table 116. Innovagen Product Features and Attributes
Table 117. Innovagen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Innovagen Recent Developments
Table 119. Bachem Corporation Information
Table 120. Bachem Description and Major Businesses
Table 121. Bachem Product Features and Attributes
Table 122. Bachem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Bachem Recent Developments
Table 124. InnoPep Corporation Information
Table 125. InnoPep Description and Major Businesses
Table 126. InnoPep Product Features and Attributes
Table 127. InnoPep Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. InnoPep Recent Developments
Table 129. Bio-Synthesis Corporation Information
Table 130. Bio-Synthesis Description and Major Businesses
Table 131. Bio-Synthesis Product Features and Attributes
Table 132. Bio-Synthesis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Bio-Synthesis Recent Developments
Table 134. Biomatrik Corporation Information
Table 135. Biomatrik Description and Major Businesses
Table 136. Biomatrik Product Features and Attributes
Table 137. Biomatrik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Biomatrik Recent Developments
Table 139. CPC Scientific Corporation Information
Table 140. CPC Scientific Description and Major Businesses
Table 141. CPC Scientific Product Features and Attributes
Table 142. CPC Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. CPC Scientific Recent Developments
Table 144. Chinese Peptide Corporation Information
Table 145. Chinese Peptide Description and Major Businesses
Table 146. Chinese Peptide Product Features and Attributes
Table 147. Chinese Peptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Chinese Peptide Recent Developments
Table 149. Hangzhou All Peptide Corporation Information
Table 150. Hangzhou All Peptide Description and Major Businesses
Table 151. Hangzhou All Peptide Product Features and Attributes
Table 152. Hangzhou All Peptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Hangzhou All Peptide Recent Developments
Table 154. WuXi Discovery Services Corporation Information
Table 155. WuXi Discovery Services Description and Major Businesses
Table 156. WuXi Discovery Services Product Features and Attributes
Table 157. WuXi Discovery Services Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. WuXi Discovery Services Recent Developments
Table 159. Raw Materials Key Suppliers
Table 160. Distributors List
Table 161. Market Trends and Market Evolution
Table 162. Market Drivers and Opportunities
Table 163. Market Challenges, Risks, and Restraints
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Cyclic Peptide Service Product Picture
Figure 2. Global Cyclic Peptide Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Cyclic Peptide Custom Synthesis Service Product Picture
Figure 4. Cyclic Peptide Structure Analysis Services Product Picture
Figure 5. Cyclic Peptide Biological Activity Evaluation Services Product Picture
Figure 6. Others Product Picture
Figure 7. Global Cyclic Peptide Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Biopharmaceutical
Figure 9. Scientific Research
Figure 10. Others
Figure 11. Cyclic Peptide Service Report Years Considered
Figure 12. Global Cyclic Peptide Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 14. Global Cyclic Peptide Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Cyclic Peptide Service Revenue Market Share by Region (2020-2031)
Figure 16. Global Cyclic Peptide Service Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Cyclic Peptide Custom Synthesis Service Revenue Market Share by Player in 2024
Figure 19. Cyclic Peptide Structure Analysis Services Revenue Market Share by Player in 2024
Figure 20. Cyclic Peptide Biological Activity Evaluation Services Revenue Market Share by Player in 2024
Figure 21. Others Revenue Market Share by Player in 2024
Figure 22. Global Cyclic Peptide Service Revenue Market Share by Type (2020-2031)
Figure 23. Global Cyclic Peptide Service Revenue Market Share by Application (2020-2031)
Figure 24. North America Cyclic Peptide Service Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Cyclic Peptide Service Revenue (US$ Million) in 2024
Figure 26. North America Cyclic Peptide Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Cyclic Peptide Service Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Cyclic Peptide Service Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Cyclic Peptide Service Revenue (US$ Million) in 2024
Figure 33. Europe Cyclic Peptide Service Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Cyclic Peptide Service Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 36. France Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Cyclic Peptide Service Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Cyclic Peptide Service Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Cyclic Peptide Service Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Cyclic Peptide Service Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 48. India Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Cyclic Peptide Service Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Cyclic Peptide Service Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Cyclic Peptide Service Revenue (US$ Million) in 2024
Figure 56. Central and South America Cyclic Peptide Service Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Cyclic Peptide Service Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Cyclic Peptide Service Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Cyclic Peptide Service Revenue (US$ Million) in 2024
Figure 62. South America Cyclic Peptide Service Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Cyclic Peptide Service Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Cyclic Peptide Service Revenue (2020-2025) & (US$ Million)
Figure 68. Cyclic Peptide Service Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
